title: Analysis of cyclin B1 and CDK activity during apoptosis induced by camptothecin treatment.
abstract: We have studied the role of cyclins and cyclin-dependent kinase (CDK) activity in apoptosis induced by camptothecin (CPT). In this model, 22% of the cells stain for annexin-V at 24 h and then proceed to be 93% positive by 72 h. This time window permits the analysis of cyclins in cells that are committed to apoptosis but not yet dead. We provide evidence that cyclin protein levels and then associated kinase levels increase after CPT treatment. Strikingly, cyclin B1 and cyclin E1 proteins are present at the same time in CPT treated HT29 cells. Although cyclin B1 and E1 CDK complexes are activated in CPT treated cells, only the cyclin B1 complex is required for apoptosis since reduction of cyclin B1 by RNAi or roscovitine treatment reduces the number of annexin-V-stained cells. We have detected poorly organized chromosomes and phosphorylated histone H3 epitopes at the time of maximum cyclin B1/CDK kinase activity in CPT-treated cells, which suggests that these cells enter a mitotic catastrophe. Understanding which CDKs are required for apoptosis may allow us to better adapt CDK inhibitors for use as anti-cancer compounds.
authors.affiliation: Institut de Recherches Servier, Cancer Drug Discovery, Croissy-sur-Seine, France.
authors.forename: A
authors.initials: A
authors.lastname: Borgne
authors.forename: I
authors.initials: I
authors.lastname: Versteege
authors.forename: M
authors.initials: M
authors.lastname: Mahé
authors.forename: A
authors.initials: A
authors.lastname: Studeny
authors.forename: S
authors.initials: S
authors.lastname: Léonce
authors.forename: I
authors.initials: I
authors.lastname: Naime
authors.forename: M
authors.initials: M
authors.lastname: Rodriguez
authors.forename: J A
authors.initials: JA
authors.lastname: Hickman
authors.forename: L
authors.initials: L
authors.lastname: Meijer
authors.forename: R M
authors.initials: RM
authors.lastname: Golsteyn
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D001483:Base Sequence; D002166:Camptothecin / Q000494:pharmacology*; D002453:Cell Cycle; D019925:Cyclin A / Q000378:metabolism; D019926:Cyclin B / Q000378:metabolism*; D056744:Cyclin B1; D019927:Cyclin E / Q000378:metabolism; D018844:Cyclin-Dependent Kinases / Q000378:metabolism*; D017931:DNA Primers; D004591:Electrophoresis, Polyacrylamide Gel; D005455:Fluorescent Antibody Technique; D019073:HT29 Cells; D006801:Humans; D034622:RNA Interference
chemical_list: D000972:Antineoplastic Agents, Phytogenic; C534699:CCNB1 protein, human; D019925:Cyclin A; D019926:Cyclin B; D056744:Cyclin B1; D019927:Cyclin E; D017931:DNA Primers; D018844:Cyclin-Dependent Kinases; D002166:Camptothecin